PBS with 0.02% sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
0.5mg/ml(Please refer to the vial label for the specific concentration.)
Synthetic peptide: APTPGPGTPAERHADG, corresponding to amino acids 44-59 of Human BACE 2.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
ALP56, DRAP, 605668, Q9Y5Z0, CEAP1, BAE2, CDA13, BACE2, AEPLC, ASP21, ASP1, 25825
Accumulation of the amyloid-b (Ab) plaque in the cerebral cortex is a critical event in the pathogenesis of Alzheimer's disease. Ab peptide is generated by proteolytic cleavage of the b-amyloid protein precursor(APP) at b- and g-sites by proteases. The long-sought-secretase was recently identified by several groups independently and designated beta-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2) (1-4). BACE/Asp2 is a novel transmembrane aspartic protease and co-localizes with APP. A BACE homolog was recently cloned and designated BACE2, Asp1, DRAP (for Down region aspartic protease), and memapsin 1 (4-9). BACE2 also cleaves APP at b-site and at a different site within Ab (8). BACE2 locates on chromosome 21q22.3, the so-called Down critical region, suggesting thatBACE2 and Ab may also contribute to the pathogenesis of Down syndrome (6,7)